HIV / AIDS

Gilead is committed to pursuing innovation in HIV across the spectrum of care. We are working to address remaining needs in both prevention and treatment. And, we are focused on discovery research that could potentially, one day, lead to a cure.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

Emtricitabine and tenofovir alafenamide

Potential Indication: PrEP

Phase 1

Phase 2

Phase 3

GS-6207 (Capsid Inhibitor)

Potential Indication: HIV/AIDS

Phase 1

Phase 2

Phase 3

Vesatolimod (TLR-7 agonist)

Potential Indication: HIV/AIDS

Phase 1

Phase 2

Phase 3

Elipovimab (bNab)

Potential Indication: HIV/AIDS

Phase 1

Phase 2

Phase 3

Liver Diseases

Gilead’s liver disease research focuses on investigating medicines for patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) and for potentially curing patients chronically infected with the hepatitis B virus (HBV).

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

Cilofexor (FXR agonist)

Potential Indication: NASH

Phase 1

Phase 2

Phase 3

Cilofexor (FXR agonist)

Potential Indication: Primary Biliary Cirrhosis

Phase 1

Phase 2

Phase 3

Cilofexor (FXR agonist)

Potential Indication: Primary Sclerosing Cholangitis

Phase 1

Phase 2

Phase 3

Firsocostat (ACC Inhibitor)

Potential Indication: NASH

Phase 1

Phase 2

Phase 3

Selgantolimod (TLR-8 agonist)

Potential Indication: HBV

Phase 1

Phase 2

Phase 3

GS-4224 (PD-L1 Inhibitor)

Potential Indication: HBV

Phase 1

Phase 2

Phase 3

Hematology / Oncology

Gilead is advancing a pipeline of cancer therapies in the areas of cell therapy, immuno-oncology and targeted therapies. Following the 2017 acquisition of Kite Pharma, Inc., our leading cell therapy pipeline now includes investigational cell therapies and next-generation technologies for a range of hematologic malignancies and solid tumors.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

GS-1423 (bi-specific antibody)

GS-4224 (oral PD-L1 inhibitor)

Inflammation / Respiratory

Gilead is advancing a pipeline of novel investigational agents for inflammatory diseases, addressing multiple targets with potential application across a broad range of disorders.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

Filgotinib (JAK1 inhibitor)

Potential Indication: Rheumatoid Arthritis

Phase 1

Phase 2

Phase 3

Filgotinib (JAK1 inhibitor)

Potential Indication: Crohn's Disease

Phase 1

Phase 2

Phase 3

Filgotinib (JAK1 inhibitor)

Potential Indication: Ulcerative Colitis

Phase 1

Phase 2

Phase 3

Filgotinib (JAK-1 inhibitor)

Potential Indication: Psoriatic Arthritis

Phase 1

Phase 2

Phase 3

Filgotinib (JAK1 inhibitor)

Potential Indication: Inflammatory Diseases

Phase 1

Phase 2

Phase 3

Filgotinib (JAK-1 inhibitor)

Potential Indication: Ankylosing Spondylitis

Phase 1

Phase 2

Phase 3

GS-9876 (Syk inhibitor)

Potential Indication: Sjogren’s Syndrome

Phase 1

Phase 2

Phase 3

GS-9876 (Syk inhibitor)

Potential Indication: Lupus

Phase 1

Phase 2

Phase 3

GS-4875 (TPL2 inhibitor)

Potential Indication: Ulcerative Colitis

Phase 1

Phase 2

Phase 3

GLPG-1690

Potential Indication: Idiopathic Pulmonary Fibrosis

Phase 1

Phase 2

Phase 3

GLPG-1690

Potential Indication: Systemic Sclerosis

Phase 1

Phase 2

Phase 3

Selonsertib (ASK-1 inhibitor)

Potential Indication: DKD

Phase 1

Phase 2

Phase 3

Other

Gilead is collaborating with U.S. Department of Defense, Centers for Disease Control and Prevention, and National Institutes of Health as well as multiple academic institutions to discover and develop novel antivirals for highly pathogenic infections and neglected/emerging viral diseases, including Ebola.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

Remdesivir (GS-5734, Nuc inhibitor)

Potential Indication: Ebola Virus Infection

Phase 1

Phase 2

Phase 3

Some of the content on this page is not intended for users outside the US.